Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $750

Benzinga Newsdesk www.benzinga.com Negative 89.9%

Neg 89.9% Neu 0% Pos 0%

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the price target from $785 to $750.